Eli Lilly has not yet submitted a biologics license application for retatrutide, the investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. Company statements confirm plans to file in the first quarter of 2027 after completing the chemistry, manufacturing, and controls package and additional Phase 3 TRIUMPH program readouts. With only weeks remaining in 2026, standard FDA review timelines—typically six to ten months post-submission—make approval this year improbable. Positive weight-loss data, including up to 25% reductions in recent trials, support future review but do not accelerate the regulatory process. An unexpected early filing combined with priority review could theoretically shift timelines, though no such developments have been indicated.